Literature DB >> 28450233

Revisiting Adjuvant Radiotherapy After Gross Total Resection of World Health Organization Grade II Meningioma.

Christopher S Graffeo1, Heather E Leeper2, Avital Perry1, Joon H Uhm3, Daniel J Lachance3, Paul D Brown4, Daniel J Ma4, Jamie J Van Gompel1, Caterina Giannini5, Derek R Johnson6, Aditya Raghunathan7.   

Abstract

BACKGROUND: Atypical meningioma is a World Health Organization grade II tumor with intermediate prognosis and risk of recurrence. Optimal management after gross total resection (GTR) is controversial, with observation versus adjuvant radiotherapy (RT) contentiously debated.
METHODS: Pathologic review was performed of all atypical meningiomas diagnosed at our institution from 1988 to 2011. Retrospective chart review documented patient demographics, extent of surgical resection, history of radiation therapy, progression-free survival (PFS), and overall survival (OS). A supplemental systematic literature review was completed in which English-language articles published since 1979 comparing observation and RT after GTR of atypical meningioma were surveyed.
RESULTS: Sixty-nine patients met inclusion criteria. Sixty-one underwent observation, and 8 received RT. Overall, 15 observation and 3 patients undergoing RT experienced tumor recurrence (5-year PFS 79% vs. 88%; P = 0.67); 19 observation and 2 patients undergoing RT died (5-year OS 89% vs. 83%; P = 0.68). Systematic review identified 9 preceding studies reporting extractable data comparing observation and RT outcomes after GTR. Recurrence was 18% and 19% after observation and RT (P = 0.9); total survival was 84% and 93% (P = 0.2). At 5 years, PFS was 81% after observation and 88% after RT (P = 0.2), whereas survival was 87% after observation and 96% after RT (P = 0.4).
CONCLUSIONS: Observation alone after GTR of atypical meningioma was not associated with increased risk of tumor recurrence or mortality. Although some preceding authors advocate for RT based on empiric experience, a systematic review also suggests that observation may provide equivalent PFS and OS to RT. Taken together, these findings indicate that observation after GTR may be a safe alternative to RT.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atypical meningioma; Observation; Overall survival; Progression-free survival; Radiotherapy; Systematic review

Mesh:

Year:  2017        PMID: 28450233     DOI: 10.1016/j.wneu.2017.04.095

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  17 in total

Review 1.  Updates in the management of intradural spinal cord tumors: a radiation oncology focus.

Authors:  Rupesh Kotecha; Minesh P Mehta; Eric L Chang; Paul D Brown; John H Suh; Simon S Lo; Sunit Das; Haider H Samawi; Julia Keith; James Perry; Arjun Sahgal
Journal:  Neuro Oncol       Date:  2019-06-10       Impact factor: 12.300

2.  The role of single-fraction stereotactic radiosurgery for atypical meningiomas (WHO grade II): treatment results based on a 25-year experience.

Authors:  Hirotaka Hasegawa; Kunal Vakharia; Michael J Link; Scott L Stafford; Paul D Brown; Ian F Parney; Terry C Burns; Elizabeth S Yan; Anita Mahajan; Nadia N Laack; Bruce E Pollock
Journal:  J Neurooncol       Date:  2021-10-27       Impact factor: 4.130

3.  Racial and Socioeconomic Disparities in Patients With Meningioma: A Retrospective Cohort Study.

Authors:  Hudin N Jackson; Caroline C Hadley; A Basit Khan; Ron Gadot; James C Bayley; Arya Shetty; Jacob Mandel; Ali Jalali; K Kelly Gallagher; Alex D Sweeney; Arif O Harmanci; Akdes S Harmanci; Tiemo Klisch; Shankar P Gopinath; Ganesh Rao; Daniel Yoshor; Akash J Patel
Journal:  Neurosurgery       Date:  2022-01-01       Impact factor: 5.315

Review 4.  Role of adjuvant radiotherapy in atypical (WHO grade II) and anaplastic (WHO grade III) meningiomas: a systematic review.

Authors:  P D Delgado-López; E M Corrales-García
Journal:  Clin Transl Oncol       Date:  2020-07-10       Impact factor: 3.405

5.  Differentially Expressed MicroRNAs in Radioresistant and Radiosensitive Atypical Meningioma: A Clinical Study in Chinese Patients.

Authors:  Xiaokang Zhang; Guobin Zhang; Huawei Huang; Haoyi Li; Song Lin; Yonggang Wang
Journal:  Front Oncol       Date:  2020-04-30       Impact factor: 6.244

6.  The Sovereignty of Primary Cranial Tumors-Meningiomas: Vetting the Cardinal Epidemiological Features.

Authors:  Alqroom Rami; Eteiwi Suzan; Aldrous Rafeed; Al Manaseer Nooruddeen; Arabiyat Lamees; Alshurbaji Duaa; Abu Nowar Hussam; Al Shurbaji Amer
Journal:  Med Arch       Date:  2018-12

7.  Effectiveness of Postoperative Adjuvant Radiotherapy in Atypical Meningioma Patients After Gross Total Resection: A Meta-Analysis Study.

Authors:  Lingzhe He; Buyi Zhang; Jianmin Zhang; Zhige Guo; Feina Shi; Qiang Zeng
Journal:  Front Oncol       Date:  2021-01-15       Impact factor: 6.244

Review 8.  Adjuvant radiotherapy versus observation following gross total resection for atypical meningioma: a systematic review and meta-analysis.

Authors:  Se-Woong Chun; Kyung Min Kim; Min-Sung Kim; Ho Kang; Yun-Sik Dho; Youngbeom Seo; Jin Wook Kim; Yong Hwy Kim; Chul-Kee Park
Journal:  Radiat Oncol       Date:  2021-02-17       Impact factor: 3.481

Review 9.  Malignant intraventricular meningioma: literature review and case report.

Authors:  Francesco Maiuri; Giuseppe Mariniello; Marcello Barbato; Sergio Corvino; Elia Guadagno; Lorenzo Chiariotti; Marialaura Del Basso De Caro
Journal:  Neurosurg Rev       Date:  2021-06-23       Impact factor: 3.042

10.  A National Consensus Survey for Current Practice in Brain Tumor Management II: Diffuse Midline Glioma and Meningioma.

Authors:  Sung Kwon Kim; Hong In Yoon; Wan Soo Yoon; Chul Kee Park; Youn Soo Lee; Ho Shin Gwak; Jin Mo Cho; Jangsup Moon; Kyung Hwan Kim; Se Hoon Kim; Young Il Kim; Young Zoon Kim; Ho Sung Kim; Yun Sik Dho; Jae Sung Park; Ji Eun Park; Youngbeom Seo; Kyoung Su Sung; Jin Ho Song; Chan Woo Wee; Se Hoon Lee; Do Hoon Lim; Jung Ho Im; Jong Hee Chang; Myung Hoon Han; Je Beom Hong; Kihwan Hwang
Journal:  Brain Tumor Res Treat       Date:  2020-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.